Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|August 24, 2020
Catalent to Manufacture Drug Substance for AstraZeneca’s COVID-19 Vaccine Candidate
Catalent will manufacture drug substance for AZD1222 at its Harmans, MD facility.
Advertisement
Catalent Cell & Gene Therapy will manufacture drug substance for AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222, at Catalent’s commercial gene therapy manufacturing facility located in Harmans, MD, the company announced in an August 24, 2020 press release. Beginning in the third quarter of 2020, Catalent will run multiple production trains in parallel to produce the vaccine candidate. The facility, located near the Baltimore-Washington International airport, is equipped with single-use technology and has more than 200,000-ft2 of late-stage clinical and commercial-stage gene therapy production.
Catalent previously announced it would provide large-scale vial filling and packaging of AZD1222 at its facility in Anagni, Italy. AZD1222 is currently in clinical trials; it was co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca.
“We are pleased to have the capabilities at our flagship Catalent Gene Therapy site to expand our support for the AstraZeneca program, while continuing to serve our current gene therapy customers. Our gene therapy team is proud to join our Catalent Biologics colleagues at the Anagni site in the advancement of AstraZeneca’s COVID-19 vaccine candidate,” said Manja Boerman, president, Catalent Cell & Gene Therapy, in the press release.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement